ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 360

Sarcoidosis Induced By Immune Check Point Inhibitors

Noémie Chanson1, Pauline Pradère2, Anne-Laure Voisin3, Stéphane Champiat4, Aurélien Marabelle4 and Olivier Lambotte5, 1Internal Medicine, Hopital Bicetre, LE KREMLIN BICETRE, France, 2Hopital Marie Lannelongue, Le Plessis Robinson, France, 3Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, 4Drug Development Department, Gustave Roussy Institut, Villejuif, France, 5Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cancer treatments and sarcoidosis, Immunotherapy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune check point inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have demonstrated improved survival for multiple cancers but have been associated with immune related adverse events (IRAEs). Granulomatosis have been rarely reported.

Methods: We described patients with granulomatous /sarcoid-like reactions among those receiving anti-PD-1(L1) antibody included in the prospective registry REISAMIC (“Registry of Severe Adverse Events of Immunomodulating Monoclonal Antibodies in Oncology”) between June 2014 and December 2017.

Results: Out of 657 patients under ICIs, 7 cases (1%) developed sarcoid like reactions. ICI regimens included pembrolizumab (4 patients), nivolumab (3 patients) including one in association with ipilimumab, and one combined with an antiangiogenic thyrosine kinase inhibitor. Five patients had melanoma and 2 patients had renal cell carcinoma. Five patients had partial or complete response under immunotherapy while 2 patients had disease progression. Granulomatous reaction occured at a median time of 4 months after beginning the ICI. None patient had preexisting sarcoidosis or autoimmune disease. Granulomatosis involved lymph nodes in 7 cases (including lung in 6 cases), skin in 3 cases , and uveitis in 1 case. Patients were often asymptomatic (mediastinal and hilar lymphadenopathy discovered on radiological evaluation). Three patients developped granulomatous lesions on scars. These clinical presentations were highly suggestive of sarcoidosis diagnosis, confirmed by histology (skin biopsy, pulmonary biopsy in 1 case each, ultrasounded guided endobrachial fine needle aspiration in 3 cases, mediastinoscopy in 1 case). All biopsies were performed in order to avoid cancer progression. No other alternative diagnosis was identified. Bronchoalveolar lavage revealed lymphocytic alveolitis in 2 patients. Pulmonary function tests, cardiac evaluation, and calcemia were normal. Angiotensin converting enzyme levels were in the normal range for 6 out 6 patients. No patient needed corticosteroid treatment while 1 patient required hydroxychloroquine or cutaneous disease. Despite these IRAEs, immunotherapy was continued for 3 patients. Prognostic was good and lymphadenopathy and pulmonary infiltrate and skin granulomas improved in most cases particularly when ICI was stopped.

Conclusion: ICI induced sarcoidosis reactions are rare and most often benign.


Disclosure: N. Chanson, None; P. Pradère, None; A. L. Voisin, None; S. Champiat, None; A. Marabelle, None; O. Lambotte, None.

To cite this abstract in AMA style:

Chanson N, Pradère P, Voisin AL, Champiat S, Marabelle A, Lambotte O. Sarcoidosis Induced By Immune Check Point Inhibitors [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/sarcoidosis-induced-by-immune-check-point-inhibitors/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sarcoidosis-induced-by-immune-check-point-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences